How to cite item

INFORM; C-TONG 0805: A multicenter, double blind randomizedphase III trial of maintenance gefitinib compared to placebo inadvanced non-small cell lung cancer

   
@article{TLCR418,
	author = {Thomas E. Stinchcombe},
	title = {INFORM; C-TONG 0805: A multicenter, double blind randomizedphase III trial of maintenance gefitinib compared to placebo inadvanced non-small cell lung cancer},
	journal = {Translational Lung Cancer Research},
	volume = {1},
	number = {2},
	year = {2012},
	keywords = {},
	abstract = {The standard first-line therapy for patients with locallyadvanced or metastatic non-small cell lung cancer(NSCLC) is platinum-based chemotherapy (1). Withstandard first line platinum-based therapy approximately75% of patients will obtain disease control, the medianprogression-free survival (PFS) is 4-6 months, and medianoverall survival (OS) is 10-13 months (2-5). Phase III trialsthat investigated a longer duration compared to a shorterduration of platinum-based therapy failed to reveal animprovement in OS with the longer duration of therapy(6-9).},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/418}
}